438 related articles for article (PubMed ID: 32641447)
1. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients.
Rueda-Gotor J; Ferraz-Amaro I; Genre F; González Mazón I; Corrales A; Portilla V; Llorca J; Agudo-Bilbao M; Aurrecoechea E; Expósito R; Hernández-Hernández V; Quevedo-Abeledo JC; Rodríguez-Lozano C; Lopez-Medina C; Ladehesa-Pineda ML; Castañeda S; Vicente EF; Fernández-Carballido C; Martínez-Vidal MP; Castro-Corredor D; Anino-Fernández J; Peiteado D; Plasencia-Rodríguez C; Vivar MLG; Galíndez-Agirregoikoa E; Perez EM; Fernández Díaz C; Blanco R; González-Gay MÁ
Semin Arthritis Rheum; 2022 Dec; 57():152096. PubMed ID: 36150319
[TBL] [Abstract][Full Text] [Related]
3. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
4. Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort.
van Lunteren M; Sepriano A; Landewé R; Sieper J; Rudwaleit M; van der Heijde D; van Gaalen F
Arthritis Res Ther; 2018 Aug; 20(1):166. PubMed ID: 30075809
[TBL] [Abstract][Full Text] [Related]
5. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
[TBL] [Abstract][Full Text] [Related]
6. Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts.
Ez-Zaitouni Z; Hilkens A; Gossec L; Berg IJ; Landewé R; Ramonda R; Dougados M; van der Heijde D; van Gaalen F
Arthritis Res Ther; 2017 May; 19(1):118. PubMed ID: 28569222
[TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.
Stolwijk C; Essers I; van Tubergen A; Boonen A; Bazelier MT; De Bruin ML; de Vries F
Ann Rheum Dis; 2015 Jul; 74(7):1373-8. PubMed ID: 24658834
[TBL] [Abstract][Full Text] [Related]
9. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.
Essers I; Ramiro S; Stolwijk C; Blaauw M; Landewé R; van der Heijde D; Van den Bosch F; Dougados M; van Tubergen A
Rheumatology (Oxford); 2015 Apr; 54(4):633-40. PubMed ID: 25234663
[TBL] [Abstract][Full Text] [Related]
10. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
11. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
14. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
16. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
Fröhlich F; Micheroli R; Hebeisen M; Kissling S; Bürki K; Exer P; Bräm R; Niedermann K; Möller B; Nissen MJ; Kyburz D; Andor M; Distler O; Scherer A; Ciurea A
Clin Rheumatol; 2023 May; 42(5):1267-1274. PubMed ID: 36574181
[TBL] [Abstract][Full Text] [Related]
17. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
18. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
20. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS.
Essers I; Ramiro S; Stolwijk C; Blaauw M; Landewé R; van der Heijde D; van den Bosch F; Dougados M; van Tubergen A
Clin Exp Rheumatol; 2016; 34(2):214-21. PubMed ID: 26843505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
